Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety

University of Medicine and Dentistry of New Jersey18 enrolled

Overview

This study will determine the efficacy of a medication switch to Aripiprazole for the treatment of schizophrenia or schizoaffective disorder in patients with moderate to high symptoms of social anxiety. Specifically the study will test the possibility that a medication switch to Aripiprazole reduces symptoms of social anxiety in this patient population.

Although research has shown that social anxiety is very common among patients suffering from schizophrenia or schizoaffective disorder, it is rarely diagnosed and treated in this patient population. This study will determine the efficacy of a medication switch to Aripiprazole for the treatment of schizophrenia in patients with moderate to high symptoms of social anxiety. Specifically the study will test the possibility that a medication switch to Aripiprazole reduces symptoms of social anxiety in this patient population. In addition, the study will test the possibility that Aripiprazole significantly improves social adjustment, quality of life and level of functioning in these patients. The study may also assess the ability of Aripiprazole to reduce sexual dysfunction.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Schizophrenia Schizoaffective Disorder Social Anxiety Disorder

Interventions

AripiprazoleDRUG

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria 1. Patients meeting DSM IV diagnostic criteria for schizophrenia or schizoaffective disorder. 2. Patients presenting with comorbid social anxiety symptoms of moderate to high severity are eligible for participation in the study. Only patients with LSAS scores above 30\* qualify for the study. 3. Age 18-65 4. Gender: males or females 5. Females: non-pregnant, not of child-bearing potential; if of child-bearing age must be on contraceptive such as pill or shot (condom alone not sufficient) 6. Good general health Exclusion Criteria: 1. Patient does not meet DSM IV diagnostic criteria for schizophrenia or schizoaffective disorder 2. Patient carries a diagnosis of dementia, degenerative CNS disorders, mental retardation, substance abuse or dependence other than nicotine dependence or alcohol abuse will be excluded from the study. 3. Patients with acute medical conditions are not eligible. 4. Patients allergic or otherwise intolerant or non-responsive to Aripiprazole 5. Patient with history of suicidal, homicidal or assaultive plans or attempts in the past 6 months. 6. Clinically significant EKG or lab abnormalities

Locations (1)

Robert Wood Johnson Medical School - Psychiatry Dept.

Piscataway, New Jersey, United States

Outcomes

Primary Outcomes

Liebowitz Social Anxiety Scale- Change from Baseline to Final Visit

Sheehan Disability Scale- Change from Baseline to Final Visit

Lehman Quality of Life Interview- Change from Baseline to Final Visit

Secondary Outcomes

Instrumental Activities of Daily Living-Change from Baseline to Final Visit

Clinical Global Impression scales [CGI]and [CGI-C]- change from Baseline to Final Visit.

Ultimate game paradigm as a measure of social cohesion- Change from Baseline to Final Visit

Arizona sexual dysfunction scale- Change from Baseline to Final Visit

COSAPSQ -Change from Baseline to Final Visit

HAM-D-Change from Baseline to Final Visit

PANSS- Change from Baseline to Final Visit

CAGE -Change from Baseline to Final Visit

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.